Experts  are now agreeing that companies are beeing too agressive in moving into clinical trials with limited data.The Incyte trial failure is an indication of that. But it also shouldn’t wipe out all the enthusiasm about checkpoint inhibition and immunotherapy for cancer, which has shown success.